» Articles » PMID: 23378706

Chemical Peels for Melasma in Dark-skinned Patients

Overview
Date 2013 Feb 5
PMID 23378706
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Melasma is a common disorder of hyperpigmentation, which has a severe impact on the quality of life. Inspite of tremendous research, the treatment remains frustrating both to the patient and the treating physician. Dark skin types (Fitzpatrick types IV to VI) are especially difficult to treat owing to the increased risk of post-inflammatory hyperpigmentation (PIH). The treatment ranges from a variety of easily applied topical therapies to agents like lasers and chemical peels. Peels are a well-known modality of treatment for melasma, having shown promising results in many clinical trials. However, in darker races, the choice of the peeling agent becomes relatively limited; so, there is the need for priming agents and additional maintenance peels. Although a number of new agents have come up, there is little published evidence supporting their use in day-to -day practice. The traditional glycolic peels prove to be the best both in terms of safety as well as efficacy. Lactic acid peels being relatively inexpensive and having shown equally good results in a few studies, definitely need further experimentation. We also recommend the use of a new peeling agent, the easy phytic solution, which does not require neutralisation unlike the traditional alpha-hydroxy peels. The choice of peeling agent, the peel concentration as well as the frequency and duration of peels are all important to achieve optimum results.

Citing Articles

Melasma: A Step-by-Step Approach Towards a Multimodal Combination Therapy.

Philipp-Dormston W Clin Cosmet Investig Dermatol. 2024; 17:1203-1216.

PMID: 38800358 PMC: 11128260. DOI: 10.2147/CCID.S372456.


Different therapeutic approaches in melasma: advances and limitations.

Ghasemiyeh P, Fazlinejad R, Kiafar M, Rasekh S, Mokhtarzadegan M, Mohammadi-Samani S Front Pharmacol. 2024; 15:1337282.

PMID: 38628650 PMC: 11019021. DOI: 10.3389/fphar.2024.1337282.


Cosmetic Considerations in Dark-Skinned Patients.

Harnchoowong S, Vachiramon V, Jurairattanaporn N Clin Cosmet Investig Dermatol. 2024; 17:259-277.

PMID: 38321987 PMC: 10844008. DOI: 10.2147/CCID.S450081.


Cosmetic Procedures in Patients with Skin of Color: Clinical Pearls and Pitfalls.

Desai M, Gill J, Luke J J Clin Aesthet Dermatol. 2023; 16(3):37-40.

PMID: 36950048 PMC: 10027327.


Update on Melasma-Part II: Treatment.

Cassiano D, Esposito A, da Silva C, Lima P, Dias J, Hassun K Dermatol Ther (Heidelb). 2022; 12(9):1989-2012.

PMID: 35906506 PMC: 9464276. DOI: 10.1007/s13555-022-00780-4.


References
1.
Monheit G . The Jessner's + TCA peel: a medium-depth chemical peel. J Dermatol Surg Oncol. 1989; 15(9):945-50. DOI: 10.1111/j.1524-4725.1989.tb03181.x. View

2.
Grover C, Reddu B . The therapeutic value of glycolic acid peels in dermatology. Indian J Dermatol Venereol Leprol. 2007; 69(2):148-50. View

3.
Kang W, Yoon K, Lee E, Kim J, Lee K, Yim H . Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol. 2002; 146(2):228-37. DOI: 10.1046/j.0007-0963.2001.04556.x. View

4.
Morton C, McKenna K, Rhodes L . Guidelines for topical photodynamic therapy: update. Br J Dermatol. 2008; 159(6):1245-66. DOI: 10.1111/j.1365-2133.2008.08882.x. View

5.
Grimes P, Yamada N, Bhawan J . Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol. 2005; 27(2):96-101. DOI: 10.1097/01.dad.0000154419.18653.2e. View